Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [2291]

Minimum residual disease techniques in myeloma

Dr Stefania Oliva - GIMEMA, European Myeloma Network, Italy

Minimum residual disease techniques in myeloma ( Dr Stefania Oliva - GIMEMA, European Myeloma Network, Italy )

Rescue after daratumumab failure

Prof Joseph Mikhael - Translational Genomics Research Institute (TGen), Phoenix...

Rescue after daratumumab failure ( Prof Joseph Mikhael - Translational Genomics Research Institute (TGen), Phoenix, USA )

Advances in prostate cancer in the last 10 years and a glimpse to the future

Prof Laura-Maria Krabbe, Prof Karim Fizazi and Prof Johann De Bono

Advances in prostate cancer in the last 10 years and a glimpse to the future ( Prof Laura-Maria Krabbe, Prof Karim Fizazi and Prof Johann De Bono )

Programme topics at AORTIC 2021 virtual

Dr Abubakar Bello - National Hospital, Abuja, Nigeria

Programme topics at AORTIC 2021 virtual ( Dr Abubakar Bello - National Hospital, Abuja, Nigeria )

Pathogenesis of colon adenocarcinoma in Kerala, India

Dr Prasanth Ariyannur - Amrita Institute of Medical Sciences and Research...

Pathogenesis of colon adenocarcinoma in Kerala, India ( Dr Prasanth Ariyannur - Amrita Institute of Medical Sciences and Research Center, Kochi India )

ESMO 2021: Latest in EGFR mutated advanced NSCLC

Dr Anna Minchom, Prof Natasha Leighl, Dr Victor Moreno and Dr Carlos Cabrera

ESMO 2021: Latest in EGFR mutated advanced NSCLC ( Dr Anna Minchom, Prof Natasha Leighl, Dr Victor Moreno and Dr Carlos Cabrera )

First-line nivolumab + ipilimumab + chemo in patients with advanced NSCLC and...

Dr David Paul Carbone - The Ohio State University Medical Center, Ohio, USA

First-line nivolumab + ipilimumab + chemo in patients with advanced NSCLC and brain metastases: Results From CheckMate 9LA ( Dr David Paul Carbone - The Ohio State University Medical Center, Ohio, USA )

Trastuzumab deruxtecan vs trastuzumab emtansine in patients with HER2+...

Dr Javier Cortés - Hospital Universitario Ramón y Cajal, Madrid, Spain

Trastuzumab deruxtecan vs trastuzumab emtansine in patients with HER2+ metastatic breast cancer ( Dr Javier Cortés - Hospital Universitario Ramón y Cajal, Madrid, Spain )

ESMO 2021: PARPi data and their role in mono/combination therapies

Dr Neal Shore, Prof Fred Saad, Prof Eleni Efstathiou, Prof Andrew Armstrong

ESMO 2021: PARPi data and their role in mono/combination therapies ( Dr Neal Shore, Prof Fred Saad, Prof Eleni Efstathiou, Prof Andrew Armstrong )

Radioembolisation with chemotherapy for colorectal liver metastases

Dr Mary Mulcahy - Northwestern Memorial Hospital, Chicago, USA

Radioembolisation with chemotherapy for colorectal liver metastases ( Dr Mary Mulcahy - Northwestern Memorial Hospital, Chicago, USA )

Challenges in first line ALK+ NSCLC and emerging data on ALK TKIs

Prof Sanjay Popat - The Royal Marsden Hospital, London, UK

Challenges in first line ALK+ NSCLC and emerging data on ALK TKIs ( Prof Sanjay Popat - The Royal Marsden Hospital, London, UK )

IMpower010: A Phase 3 study of atezolizumab vs best supportive care after...

Dr Enriqueta Felip - Vall d’Hebron University Hospital & Vall d’Hebron...

IMpower010: A Phase 3 study of atezolizumab vs best supportive care after adjuvant chemotherapy in stage IB-IIIA NSCLC ( Dr Enriqueta Felip - Vall d’Hebron University Hospital & Vall d’Hebron Institute of Oncology, Barcelona, Spain )

More from ecancer